Morgan Stanley raised the firm’s price target on Regeneron (REGN) to $767 from $756 and keeps an Overweight rating on the shares following a Q3 beat on the top and bottom line. While noting that commentary on 2026 expenses suggests upward pressure relative to consensus, the firm also says it is “encouraged” that the company continues to work towards a path to resolution of Eylea HD fill and finish issues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
- Early notable gainers among liquid option names on October 28th
- Morning Movers: UPS and PayPal jump following quarterly reports
- Regeneron reports Q3 non-GAAP EPS $11.83, consensus $9.64
- Regeneron still sees 2025 CapEx $880M-$950M